logo
Study Reveals Empathy-Focused Interventions Have the Same Impact as Prescription Medications for Diabetes Control

Study Reveals Empathy-Focused Interventions Have the Same Impact as Prescription Medications for Diabetes Control

Business Wire17-06-2025
AUSTIN, Texas--(BUSINESS WIRE)--A recent clinical trial from the founders of Beheld and a research team at the Dell Medical School has demonstrated that science-backed human connection can drive clinically relevant health improvements for health plan members. The study, published in JAMA Network Open, found that consistent, empathy-focused phone calls led to significant improvement in mental health and blood sugar control for adults with diabetes. This research highlights a cost-effective model for managing various conditions, especially for individuals with limited access to traditional mental health and support services.
This research builds on Kahlon's previous work studying the broader benefits of empathetic phone calls. In 2021, Kahlon and her team published a study that found 10-minute Sunshine Connections improved mental health for elderly patients.
Share
During the six-month clinical trial, 260 patients of the Federally Qualified Health Center (FQHC) Lone Star Circle Care with uncontrolled diabetes were split randomly into two groups—one receiving standard care and the other receiving both standard care and consistent phone calls. Referred to as Sunshine Connections, these calls were made by empathetically talented nonmedical staff, creating opportunities for participants to share their experiences and day-to-day challenges in living with diabetes. This human-centered approach empowered trial participants to receive support at their own pace, fostering a strong personal connection and ongoing engagement with their callers beyond the clinical setting.
At the end of six months, the participants receiving Sunshine Connections saw:
Improved Blood Sugar Control: Patients saw an average HbA1c reduction of 0.7%, compared with no significant change in the control group.
Greater Impact for Patients with Mild or Greater Depressive Symptoms: Patients reporting mild depressive symptoms saw even larger reductions, with average HbA1c improvements of 1.1%.
High Satisfaction: Nearly all participants receiving Sunshine Connections rated them as very or extremely beneficial to their well-being.
'At a time when workforce shortages challenge health care delivery, this study underscores the profound clinical impact nonclinical staff can make,' said Jon Calvin, CEO of Lone Star Circle of Care. 'By leveraging trained laypeople, we're demonstrating that empathy, connection and intentional engagement can lead to measurable health improvements. In a world where medicine is increasingly fast-paced and technology-driven, this work reminds us that human connection remains at the heart of effective care. Empathy not only enhances patient engagement but empowers individuals to take meaningful steps toward better health outcomes.'
This research builds on the study's lead author, Maninder Kahlon, Ph.D., previous work studying the broader benefits of empathetic phone calls. In 2021, Kahlon and her team published a study that found 10-minute Sunshine Connections improved loneliness, depression, anxiety and overall mental health among mostly homebound, older adults. After just a four-week trial, participants reported feeling 20% less lonely on average. Symptoms of anxiety and depression also notably decreased, with more than a 30% decrease on the GAD-7 scale and 24% decrease on the PHQ-8 scale, respectively. Beheld is also working on a study examining the impact of Sunshine Connections on maternal health outcomes for Medicaid populations—this data is expected to be available by the end of summer 2025.
'Care relationships have deteriorated because healthcare rewards high-cost care over long-term human connection—and technology often deepens that gap. Approaches that lack connection lead to worse health outcomes, and at this point, the traditional healthcare system is too under-resourced to solve it. Beheld is changing that,' said Maninder 'Mini' Kahlon, Ph.D., lead author of the study, co-founder and CEO of Beheld, and associate professor in the Department of Population Health at Dell Med. 'Our study found that engaging nonmedical talented individuals to provide empathetic support has a meaningful impact on health conditions like diabetes; the impact is the clinical equivalent to improvements you would see from prescription medications. This approach holds massive potential for health plans looking to address other conditions in Medicaid and Medicare Advantage member populations.'
To learn more about Beheld, visit www.beheldhealth.com
About Beheld
Beheld delivers clinically relevant health improvements for members through the power of consistent, science-backed human connection. Co-founded by Dr. Maninder Kahlon, founding Vice Dean of Dell Medical School at UT Austin, Beheld aims to redefine traditional healthcare delivery using technology as an enabler for deeper understanding and trust. Partnering with health plans to tackle their biggest challenges, Beheld leverages its empathetically talented workforce and innovative technology to source unique insights into member populations to improve outcomes, quality metrics, and cost savings. To learn more, visit www.beheldhealth.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone ® Lispro (THDB0206 injection) in People with T2D
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone ® Lispro (THDB0206 injection) in People with T2D

Business Wire

time3 hours ago

  • Business Wire

ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone ® Lispro (THDB0206 injection) in People with T2D

LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the 'Company'), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive topline results on the Phase 3 clinical trial on BioChaperone ® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation. Conducted by Tonghua Dongbao, this Phase 3 study (NCT05834868) was approved by the Chinese Regulatory Authorities (CDE 1). The randomized, open, multicenter study evaluated the safety and efficacy of THDB0206 injection compared to Humalog ® in adults with Type 2 diabetes. Dr LENG Chunsheng, President of Tonghua Dongbao, said: " THDB0206 injection is a new generation of ultra-rapid insulin that has demonstrated benefits for improving blood glucose control of adults with Type 2 diabetes compared with the standard of care Humalog ®. Tonghua Dongbao is committed to continue to innovate in the treatment of diabetes and obesity." Olivier Soula, CEO and Co-Founder of Adocia, added: " We are thrilled to share the positive results obtained with BioChaperone ® Lispro on this Phase 3 clinical trial on people with Type 2 diabetes. Given the well-known challenges in showing clinical improvement in this population with a new prandial insulin, we are particularly delighted with these findings. This milestone demonstrates Adocia's ability to advance its innovative treatments to the final stages of clinical development, within strategic partnerships. We congratulate Tonghua Dongbao's team for the quality of execution of a large Phase 3 trial of over 1,000 people.' Results A total of 1,040 Chinese adults with Type 2 diabetes with inadequate glycemic control and using daily multiple injections of insulin were randomized. After 26 weeks of treatment, HbA1c decreased significantly in both groups compared to the baseline. The reduction in the THDB0206 injection group was comparable to that of the Humalog ® group, meeting the primary endpoint. The key secondary endpoints were also demonstrated, with a statistically significant lower rise of blood glucose after a standard meal for the THDB0206 injection group, compared to the Humalog ® group. The 10-point self-monitoring blood glucose (SMBG) of patients at week 26, an important supportive endpoint of the trial, confirmed the advantage of this product in controlling postprandial blood glucose fluctuations, with a statistically improved daily blood glucose level. A series of prespecified subgroup analyzes of the primary HbA1c endpoint also fully confirmed the benefits of this product in long-term blood glucose control in patients with Type 2 diabetes. In addition, the safety and tolerability of THDB0206 injection were good. Most of the adverse events were mild or moderate, and the incidence of adverse events and hypoglycemic events were similar to those of Humalog ®. About BioChaperone ® Lispro BioChaperone ® Lispro was licensed to Tonghua Dongbao in 2018, as part of a Licensing Agreement covering China and other Asian countries 2. BioChaperone ® Lispro is an Ultra-Rapid Insulin, belonging to the latest generation of prandial insulins. It combines Adocia's proprietary BioChaperone ® technology with insulin lispro, the active ingredient in the standard of care, Humalog ® (Eli Lilly). This innovative formulation acts significantly faster than earlier insulin generations, effectively reducing post-meal hyperglycemia, which is a key contributor to long-term complications such as retinopathy, diabetic foot ulcers, or kidney failure. Additionally, its rapid elimination minimizes the risk of hypoglycemia, often caused when insulin level remains high after post-meal glucose levels have normalized. The faster action profile of BioChaperone ® Lispro associated to an excellent local tolerance enhances its compatibility with modern diabetes management systems, particularly insulin pump systems, and provides better integration into advanced treatment algorithms. Beyond its clinical advantages, the quick onset of BioChaperone ® Lispro improves quality of life by offering greater flexibility in dose timing. Patients can administer insulin at mealtime, or even right-after-mealtime, allowing for more accurate dosing based on known meal timing and content. This reduces the risks of overdosing or underdosing, which can lead to hypo- or hyperglycemia and their associated complications. The simplified dosing process eases the psychological burden on patients and caregivers, significantly alleviating the stress associated with diabetes management. About Tonghua Dongbao Tonghua Dongbao Pharmaceutical Co. Ltd (SHSE: 600867), is a pharmaceutical company based in Jilin province, China, specializing in the R&D, manufacturing and commercialization of insulins and other diabetes treatments. Tonghua Dongbao currently employs over 3,000 people and has sales of around $280 million. It has been listed on the Shanghai Stock Exchange since 1994, with a market capitalization of about $2.3 billion. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext ™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the 'Risk Factors' section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.

SunLink Health Systems, Inc. provides an Update on Proxy Voting
SunLink Health Systems, Inc. provides an Update on Proxy Voting

Business Wire

time11 hours ago

  • Business Wire

SunLink Health Systems, Inc. provides an Update on Proxy Voting

ATLANTA--(BUSINESS WIRE)--SunLink Health Systems, Inc. (NYSE American: SSY) today urges its stockholders of record as of June 20, 2025 to vote in favor of all of the proposals outlined in the definitive joint proxy statement/prospectus (the 'Proxy Statement') for the upcoming Special Meeting of SunLink stockholders to be held at 10:00 AM EDT on Tuesday, July 29, 2025 to approve the proposed Merger with Regional Health Properties, Inc. Robert M. Thornton, Jr., Chief Executive Officer of SunLink, commented, 'We appreciate the strong support from SunLink's voting stockholders and strongly urge all unvoted stockholders of record to vote FOR all proposals in order to move forward with the Merger. Both SunLink and Regional are excited about the anticipated benefits and opportunities that the Merger brings to their respective stockholders as stockholders in the combined company.' Mr. Thornton further noted that leading independent proxy advisory firm Institutional Shareholder Services Inc. ('ISS') reviewed the transaction and concluded that it is in the best interests of SunLink stockholders. ISS cited the Board's reasonable review of alternatives, the implied premium and the opportunity for SunLink stockholders to participate in the potential upside of the combined entity in their 'FOR' recommendations. 1 Approval of Proposal 1 (Approval of the Merger Agreement and related transactions, including the Merger) is of particular importance because such approval is a condition to the consummation of the Merger. Although an overwhelming majority of votes cast to date have supported Proposal 1, approval of this proposal has a higher vote threshold and requires the affirmative vote of the holders of a majority of the shares of SunLink common stock outstanding and entitled to vote at the SunLink special meeting to approve the SunLink merger proposal. The Merger cannot be consummated unless Proposal 1 approving the merger agreement and the transactions contemplated thereby, including the merger is approved by SunLink stockholders. The SunLink Board unanimously recommends that SunLink shareholders vote 'FOR' the approval of the SunLink merger proposal by voting FOR Proposal 1, as well as Proposals 2 and 3. EVERY VOTE MATTERS – NO MATTER HOW MANY SHARES YOU OWN Holders of record may vote by proxy or in person at the SunLink special meeting. If you hold your shares of SunLink common stock in your name as a holder of record, to submit a proxy, you, as a SunLink shareholder, may use one of the following methods: • Via the Internet: by visiting the website indicated on the accompanying proxy card and following the instructions. Expand • By telephone: by calling the toll-free number indicated on the accompanying proxy card and following the recorded instructions. Expand • By mail: by completing the accompanying proxy card and returning it in the postage-paid envelope. If you do not have the postage-paid envelope, please mail your completed proxy card to the following address: SunLink Health Systems, Inc., 900 Circle 75 Parkway, Suite 690, Atlanta, Georgia 30339., Attn: Corporate Secretary. Expand If you submit your proxy via the Internet or by telephone, you must do so no later than 11:59 p.m., Eastern time, on the day before the SunLink special meeting. If you vote by mail, your proxy card must be received no later than 11:59 p.m., Eastern time, on the day before the SunLink special meeting. Assistance If you need assistance with voting via the Internet, voting by telephone or completing your proxy card, or have questions regarding the SunLink special meeting, please contact SunLink at (770) 933-7000. YOUR VOTE IS IMPORTANT. VOTE TODAY! A proxy form or voting instruction form accompanied the special meeting materials. Instructions on how to vote, which vary depending on whether you are a registered or beneficial stockholder of the Company, are provided in the proxy form or voting instruction form. The proposals outlined in the Proxy include the proposed Merger with Regional. The Merger will combine SunLink's pharmacy operations with Regional's nursing home and healthcare real estate operations with the goals of increasing vertical integration, reducing operating expenses, taking advantage of economies of scale, mitigating supplier market power, and improving the financial condition of the combined company. SunLink Health Systems, Inc. is the parent company of subsidiaries that own and operate a pharmacy business in the Southeast. For additional information on SunLink Health Systems, Inc., please visit the Company's website. NO OFFER OR SOLICITATION Communications in this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the 'Securities Act'). ADDITIONAL INFORMATION The proposed merger will be submitted to both the Regional and SunLink shareholders for their consideration. In connection with the proposed merger, Regional filed a Registration Statement on Form S-4 (as supplemented or amended, the 'Registration Statement') with the U.S. Securities and Exchange Commission (the 'SEC') that includes a joint proxy statement/prospectus for Regional and SunLink (the 'joint proxy statement/prospectus'), which was sent to common stock shareholders of Regional and common stock shareholders of SunLink on or about June 30, 2025. INVESTORS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE CORRESPONDING JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. You are able to obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about SunLink and Regional, without charge, at the SEC's website ( or by accessing SunLink's website ( under the tab 'Investors' or by accessing Regional's website ( under the tab 'Investor Relations.' Copies of the joint proxy statement/prospectus have been mailed to the shareholders of SunLink and Regional who are, as of the respective record dates, entitled to vote on the merger, copies can also be obtained, without charge, by directing a request to Investor Relations, SunLink Health Systems, Inc., 900 Circle 75 Parkway, Suite 690, Atlanta, Georgia, 30339, telephone 770-933-7004 or to Investor Relations, Regional Health Properties, Inc., 1050 Crown Pointe Parkway, Suite 720, Atlanta, Georgia, 30338, telephone 678-869-5116. SunLink and Regional and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of SunLink and Regional in connection with the proposed merger. Information about the directors and executive officers of SunLink is set forth in Part III of SunLink's Amendment No. 1 to Annual Report on Form 10-K/A for the fiscal year ended June 30, 2024, which information may be updated by SunLink from time to time in subsequent filings with the SEC. Information about the directors and executive officers of Regional is set forth in Part III of Regional's Annual Report on Form 10-K for the year ended December 31, 2024, which information may be updated by Regional from time to time in subsequent filings with the SEC. Additional information about the interests of those participants and other persons who may be deemed participants in the transaction may also be obtained by reading the joint proxy statement/prospectus relating to the proposed merger. Free copies of this document may be obtained as described above. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements can often, but not always, be identified by the use of words like 'believe', 'continue', 'pattern', 'estimate', 'project', 'intend', 'anticipate', 'expect' and similar expressions or future or conditional verbs such as 'will', 'would', 'should', 'could', 'might', 'can', 'may', or similar expressions. These forward-looking statements include, but are not limited to, statements relating to the expected timing and benefits of the proposed merger between Regional and SunLink, including statements of Regional's goals, intentions and expectations; statements regarding Regional's business plan and growth strategies; and the ability of Regional to meet the continued listing requirements of the NYSE American and to maintain the listing of securities thereon. These forward-looking statements are subject to significant risks, assumptions and uncertainties that may cause results to differ materially from those set forth in forward-looking statements, including, among other things: Litigation that may be filed against Regional, SunLink, the members of the Regional Board, the members of the SunLink Board or the officers of Regional or SunLink could result in substantial costs, and the possible unexpected or adverse outcomes of such litigation, any of which could adversely affect Regional's and SunLink's ability to complete the merger on a timely basis or at all; the ability to obtain the approvals of SunLink's or Regional's shareholders, and the ability to complete the merger on the expected timeframe; the ability of SunLink to meet the continued listing requirements or rules of the NYSE American LLC, the ability of Regional to meet the requirements of the OTCQB, and the ability of Regional to meet the initial listing requirements of the NYSE American after the merger, and, as applicable, the ability to maintain the listing or trading, as applicable, of securities thereon; the risk that the businesses of Regional and SunLink will not be integrated successfully, or such integration may be more difficult, time-consuming, or costly than expected; expected revenue synergies and cost savings from the merger may not be fully realized or realized within the expected time frame; revenues following the merger may be lower than expected; customer, vendor and employee relationships and business operations may be disrupted by the merger; possible changes in economic and business conditions; the impacts of epidemics, pandemics, or other infectious disease outbreaks; the existence or exacerbation of general geopolitical instability and uncertainty; possible changes in monetary and fiscal policies, and laws and regulations; competitive factors in the healthcare industry; Regional's dependence on the operating success of its operators; the amount of, and Regional's ability to service, its indebtedness; covenants in Regional's debt agreements that may restrict its ability to make investments, incur additional indebtedness, and refinance indebtedness on favorable terms; the effect of increasing healthcare regulation and enforcement on Regional's operators and the dependence of Regional's operators on reimbursement from governmental and other third-party payors; the relatively illiquid nature of real estate investments; the impact of litigation and rising insurance costs on the business of Regional's operators; the effect of Regional's operators declaring bankruptcy, becoming insolvent, or failing to pay rent as due; the ability of any of Regional's operators in bankruptcy to reject unexpired lease obligations and to impede its ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations; Regional's ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; and other risks and factors identified in (i) SunLink's cautionary language included under the headings 'Forward-Looking Statements' and 'Risk Factors' in SunLink's Annual Report on Form 10-K for the year ended June 30, 2024, and other documents subsequently filed by SunLink with the SEC and (ii) Regional's cautionary language included under the headings 'Statement Regarding Forward-Looking Statements' and 'Risk Factors' in Regional's Annual Report on Form 10-K for the year ended December 31, 2024, and other documents subsequently filed by Regional with the SEC. Neither SunLink nor Regional undertake any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this Current Report on Form 8-K. In addition, SunLink's and Regional's past results of operations do not necessarily indicate either of their anticipated future results, whether the merger is effectuated or not. 1 Permission to cite ISS was neither sought nor obtained.

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Business Wire

time12 hours ago

  • Business Wire

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, will host its virtual R&D Day today at 1:30 PM PT. The event will highlight the company's continued momentum in advancing its novel immunotherapy platforms—TRACTr and TRACIr, as well as ARM—designed to address significant unmet needs in oncology and autoimmune diseases. 'At Janux, we are guided by a deep commitment to scientific excellence and a belief that innovation should translate into meaningful outcomes for patients,' said David Campbell, Ph.D., President and CEO of Janux Therapeutics. 'The progress we've shared today across our TRACTr, TRACIr, and ARM platforms reflects our disciplined strategy to focus first on maximizing the benefit and value of our clinical program JANX007, second to harness the value of our clinical experience by bringing forward TRACTrs where we can potentially be first- and/or best-in-class, and third to utilize our T cell engager development expertise to enable platform technologies that address other clear gaps in the treatment landscape.' Creating an Opportunity to Further Differentiate JANX007 with TRACIr Combination Janux is advancing its CD28-based TRACIr platform designed to enhance T cell activation and durability of its CD3-based TRACTr platform. TRACIr was built on the same technology with the same tumor-activation and PK design features as TRACTr and combines tumor targeting with immune costimulation. The TRACIr platform represents a strategic extension of Janux's tumor-activated approach, designed to complement and enhance the clinical potential of its TRACTr portfolio, beginning with PSMA-TRACTr JANX007. While JANX007 has already demonstrated differentiated clinical activity in late-stage metastatic castration-resistant prostate cancer (mCRPC) patients, the addition of a PSMAxCD28-TRACIr introduces a costimulatory signal that may further enhance durability of response within the tumor microenvironment. This combination has the potential to drive more prolonged anti-tumor effects without increasing systemic toxicity, positioning Janux to further differentiate JANX007 in the mCRPC treatment landscape. IND-enabling studies are underway for the PSMA-TRACIr, with clinical trials in combination with JANX007 expected to begin in the second half of 2026. Expanding the TRACTr Platform into High-Value Oncology Indications Building upon learnings from the JANX007 and JANX008 clinical programs, Janux introduced its latest trophoblast cell surface antigen 2 (TROP2) TRACTr program. This next-generation TROP2-TRACTr was engineered for potential best-in-class safety and efficacy across a broad range of TROP2-expressing tumors, including breast, lung and bladder cancers. Janux's TROP2-TRACTr exemplifies the TRACTr technology's ability to create high-value T cell engager (TCE) product candidates directed at tumor targets that contemporary TCE technologies have been unable to access due to broad healthy tissue expression. Janux's TROP2-TRACTr product candidate demonstrated strong potency across multiple tumor types, activity at low TROP2 expression levels, and was well tolerated in non-human primates with no signs of cytokine release syndrome (CRS) or healthy tissue toxicity. This preclinical data also displayed the ability to overcome limitations of existing TROP2-targeted therapies, including antibody drug conjugates. These findings support a wide therapeutic window and the potential for best-in-class performance in TROP2-expressing solid tumors. IND-enabling activities are planned in the second half of 2025. ARM Platform Redefines T-Cell Engagers for Autoimmune Disease and Oncology Janux also introduced its Adaptive Immune Response Modulator (ARM) bispecific platform, designed to overcome the limitations of conventional TCEs in autoimmune diseases and oncology. Builds upon Janux's expertise to redesign bispecific TCEs. Differentiated non-clinical profile provides best-in-class opportunity in autoimmune diseases. Potential broad applicability across multiple disease areas. Large safety window and off-the-shelf format position it for higher dosing, rapid development and potential best-in-class performance. The lead program, a CD19-ARM, has displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, supporting a potential best-in-class profile. ARMs exhibit differentiated durable T cell activity with reduced T cell exhaustion preclinically. The program demonstrated prolonged memory B-cell depletion and immune reset from a single subcutaneous dose, reflecting the durability seen with CD19 CAR-T therapies but with greater safety and convenience. ARMs displayed potential to dose to maximum efficacy while enabling safer, outpatient-friendly dosing. In non-human primates, CD19-ARM achieved deep and durable B-cell depletion in both blood and lymphoid tissues with a >100x CRS safety window. The CD19-ARM is on track for first-in-human studies to begin in the first half of 2026. Event Information To join the webcast, please visit this link, or the Events & Presentations page of the Investors section on the Company's website A replay of the webcast will be archived and available following the event. Participant Dial-In Numbers: USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Conference ID 9235403 Janux's TRACTr, TRACIr and ARM Pipeline Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux's second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Janux is also advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr for use in combination with our PSMA-TRACTr JANX007, and a TROP2-TRACTr for the treatment of TROP2+ solid tumors. Janux is also advancing its first ARM platform program candidate, a CD19-ARM for the potential treatment of autoimmune diseases toward clinical trials. About Janux Therapeutics Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned clinical trials, and the potential benefits of Janux's product candidates and platform technologies. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store